Literature DB >> 7219206

A complement inhibitor produced by Stachybotrys complementi, nov. sp. K-76, a new species of fungi imperfecti.

W Miyazaki, H Tamaoka, M Shinohara, H Kaise, T Izawa, Y Nakano, T Kinoshita, K Hong, K Inoue.   

Abstract

A complement inhibitor, K-76, was isolated and purified from the culture supernatant of a fungus, Stachybotrys complementi, nov. sp. K-76, isolated from soil of Ishigaki Island, Okinawa. K-76 is a sesquiterpene compound and it can be oxidized to a monocarboxylic derivative (K-76 COOH), the sodium salt of which is very soluble and much less toxic than K-76. K-76 and K-76 COOH both inhibited complement activation by either the classical or alternative pathway. They inhibited generation of the factor chemotactic to human polymorphonuclear leukocytes from human serum by aggregated immunoglobulin. When sensitized erythrocytes were treated with complement in the presence of K-76 COOH, the resulting unlysed cells were found to be in the state of EACl, 4b, 2a, 3b. Thus K-76 COOH is considered to block mainly the C5 intermediate step. K-76 COOH did not inhibit any proteases or esterases tested, except when tested at high concentration.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7219206     DOI: 10.1111/j.1348-0421.1980.tb02914.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  16 in total

1.  Aspergillus fumigatus complement inhibitor: production, characterization, and purification by hydrophobic interaction and thin-layer chromatography.

Authors:  R G Washburn; D J DeHart; D E Agwu; B J Bryant-Varela; N C Julian
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

2.  Multifunctional effects of anticomplementary agent K-76 on carrageenan-induced colitis in the rabbit.

Authors:  A Kitano; T Matsumoto; S Nakamura; N Oshitani; A Obata; K Okawa; Y Inoue; K Kobayashi; H Nakura
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

3.  Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes.

Authors:  H Harashima; K Sakata; K Funato; H Kiwada
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

4.  Plasma factor triggering alternative complement pathway activation by liposomes.

Authors:  K Funato; C Yamashita; J Kamada; S Tominaga; H Kiwada
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

5.  Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation.

Authors:  M Tanaka; N Murase; Q Ye; W Miyazaki; M Nomoto; H Miyazawa; R Manez; Y Toyama; A J Demetris; S Todo; T E Starzl
Journal:  Transplantation       Date:  1996-09-15       Impact factor: 4.939

6.  Significance of tumor necrosis factor (TNF) and interleukin-1 (IL-1) in the pathogenesis of fulminant hepatitis: possible involvement of serine protease in TNF-mediated liver injury.

Authors:  M Nagaki; Y Muto; H Ohnishi; H Moriwaki
Journal:  Gastroenterol Jpn       Date:  1991-08

7.  Effect of the anticomplementary agent, K-76 monocarboxylic acid, on experimental immune complex glomerulonephritis in rats.

Authors:  H Iida; K Izumino; M Asaka; M Takata; Y Mizumura; S Sasayama
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

8.  Amelioration of immune complex-mediated glomerulonephritis by synthetic protease inhibitors.

Authors:  J C Jennette; R R Tidwell; J D Geratz; D H Bing; R J Falk
Journal:  Am J Pathol       Date:  1987-06       Impact factor: 4.307

9.  A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement.

Authors:  M Ling; S J Piddlesden; B P Morgan
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

10.  Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition.

Authors:  H Miyazawa; N Murase; A J Demetris; K Matsumoto; K Nakamura; Q Ye; R Manez; S Todo; T E Starzl
Journal:  Transplantation       Date:  1995-04-27       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.